Compare Biogen Inc (BIIB) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while YieldMax NVDA Option Income Strategy ETF trades at $13.07. The key difference: Biogen Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | NVDY | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $216.63 | $17.96 |
52-Week Low | $128.93 | $11.58 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $13.06, up 2.59% today with a bullish technical signal. The ETF generates weekly dividend distributions through options strategies on NVIDIA stock, though recent news highlights concerns about opportunity cost versus direct NVIDIA ownership. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while moving averages remain bullish.
The outlook balances high income generation against capped upside potential. Investment opportunity lies in consistent weekly distributions, while primary risks include underperformance versus NVIDIA's explosive growth and the fund's strategy of selling call options that limit participation in NVIDIA's strongest rallies. The ETF appeals to income-focused investors willing to trade growth potential for regular cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
